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Abstract
Previous research suggests that brain oxidative stress and altered rodent locomotor behavior are
linked. We observed bio-behavioral changes in methionine sulfoxide reductase A knockout mice
associated with abnormal dopamine signaling. Compromised ability of these knockout mice to reduce
methionine sulfoxide enhances accumulation of sulfoxides in proteins. We examined the dopamine
D2-receptor function and expression, which has an atypical arrangement and quantity of methionine
residues. Indeed, protein expression levels of dopamine D2-receptor were higher in knockout mice
compared with wild-type. However, the binding of dopamine D2-receptor agonist was compromised
in the same fractions of knockout mice. Coupling efficiency of dopamine D2-receptors to G-proteins
was also significantly reduced in knockout mice, supporting the compromised agonist binding.
Furthermore, pre-synaptic dopamine release in knockout striatal sections was less responsive than
control sections to dopamine D2-receptor ligands. Behaviorally, the locomotor activity of knockout
mice was less responsive to the inhibitory effect of quinpirole than wild-type mice. Involvement of
specific methionine residue oxidation in the dopamine D2-receptor third intracellular loop is
suggested by in vitro studies. We conclude that ablation of methionine sulfoxide reductase can affect
dopamine signaling through altering dopamine D2-receptor physiology and may be related to
symptoms associated with neurological disorders and diseases.
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Post-translational modifications resulting from reactive oxygen species can alter the functions
of many proteins. While most protein modifications by reactive oxygen species are irreversible,
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methionine sulfoxide (MetO) modifications can be reversed by the methionine sulfoxide
reductase (Msr) system, which consists of MsrA (reduces S-MetO) and MsrB (reduces R-
MetO) (Moskovitz 2005). Reduction action of the Msr system may prevent irreversible protein
damage, contribute to cellular antioxidant resistance, and regulate protein function. Evidence
for a role of the Msr system in antioxidant defense is demonstrated by the adverse effects
resulting from MsrA ablation (Moskovitz et al. 1995, 1997, 2001). Furthermore, over-
expression of MsrA in various organisms and cells protects them from oxidative stress toxicity
(Moskovitz et al. 1998; Ruan et al. 2002; Romero et al. 2004). The MsrA null mouse (MsrA
−/−) is hypersensitive to oxidative stress, accumulates higher levels of carbonylated protein
and expresses brain pathologies associated with neurodegenerative diseases (Moskovitz et
al. 2001; Pal et al. 2007); this evidence suggests a major biological role of the Msr system.
Furthermore, the Msr enzymes have been shown to switch several proteins between non-active
and active forms by reducing specific MetO residues to methionine (Oien and Moskovitz
2008).
The MsrA−/− mouse exhibits age-dependent lower locomotor activity and abnormal gait
indices (Oien et al. 2008) relative to control mice. Lower dopamine (DA) levels are associated
with altered motor performance (Carlsson et al. 2007). Surprisingly, our recent observations
showed that MsrA−/− brains in adult mice contained significantly higher levels of DA (Oien
et al. 2008). Moreover, pre-synaptic neuronal DA in MsrA−/− striatal slices is released at higher
DA pulses than wild-type (WT) slices as measured by fast scan cyclic voltammetry. These
results raise the possibility that DA function is impaired in MsrA−/− mice. Moreover, MsrA−/
− mice were less responsive to amphetamine treatment as assayed by locomotor activity and
stereotypy, suggesting alteration of DA signaling. Dysfunctions of the corpus striatum and
dopaminergic signaling are linked to a range of disorders including Parkinson’s disease
(Hornykiewicz 1962), Huntington’s disease (Hickey et al. 2002), schizophrenia, and
obsessive-compulsive disorder (Saxena et al. 1998).
The observed MsrA−/− locomotor deficits and DA abnormalities prompted us to further
examine DA signaling events that are associated with striatal movement pathways. The
dopamine D1 receptor (D1DR) and dopamine D2 receptor (D2DR) are closely associated with
movement regulation, and theoretically are the DA receptors most related to the MsrA−/−
locomotor phenotypes (Oien et al. 2008). In addition, D2DR is also expressed in its short form
(D2DRS) that serves as an autoreceptor for dopaminergic neurons. Thus, methionine oxidation
in either the long form of D2DR or D2DRS or a combination of both may be related to the
elevation in DA levels observed in MsrA−/− brains (Oien et al. 2008). In the current study we
investigate the ligand-binding capabilities of DA receptors and their coupling efficiency to G-
proteins in MsrA−/− versus WT mice. The presented data support the hypothesis that MetO
modification to D2DRs participates in the MsrA−/− behavioral and biochemical phenotypes.
Materials and methods
Materials
The radioligands [3H]SCH23390 (85 Ci/mmol), [3H]raclopride (84 Ci/mmol), [3H]quinpirole
(50 Ci/mmol), were purchased from Perkin Elmer (Waltham, MA, USA). Non-radioactive
sulpiride, quinpirole, SKF82958, and GTPγS were purchased from Sigma, St Louis, MO, USA.
Mouse and goat antibodies against D2DR were purchased from Abcam (Cambridge, MA,
USA). Mouse β-actin antibodies were purchased from Molecular Probes, Eugene, OR, USA.
Mice
Mice used in these studies were WT (C57BL6/129 Sv) and MsrA−/− on the same genetic
background at an age of 6–8 months unless otherwise noted. Both types of mice were littermates
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born to MsrA+/− heterozygous parents (Moskovitz et al. 2001). All procedures using mice
were performed within guidelines of the NIH and KU Institutional Animal Care and Use
Committee.
Immunohistochemistry analysis
Coronal brain sections from 12-month-old WT and MsrA−/− mice were processed as 20 μm-
thick brain sections. Sections were treated with 3% H2O2 in methanol for 30 min. After
blocking with 1% bovine serum albumin and 3% horse serum in phosphate-buffered saline,
the sections were incubated for 24 h with primary goat antibodies against D2DR (1 : 500
dilution, stock concentration of 1.5 mg/mL). Sections were then incubated with biotinylated
mouse anti-goat IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), avidin–
horseradish peroxide solution, 0.015% diaminobenzidine, 0.001% H2O2, and finally counter-
stained with hematoxylin. The brain slides were washed, dehydrated, mounted, and visualized
using a brightfield microscope with a 100× objective lens.
Immunoblot analysis
Equal amounts of striatal membranal protein extracts or cytosolic brain proteins (extracted as
described below for receptors fraction) were subjected to sodium dodecyl sulfate-gel
electrophoresis. Immunoblot analyses with anti-goat D2DR antibodies (1 : 1000 dilution, stock
concentration of 1.5 mg/mL) were performed according to common procedures. β-actin
(loading control) was detected by primary anti-β-actin mouse antibodies.
Antagonists and agonists binding of D1DR and D2DR ligands
Saturation curves of receptor binding were determined by using the common membrane
filtration assay (Bylund and Toews 1993). Briefly, brains (striatal region of each mouse type)
were dissected and glass-Teflon homogenized in phosphate-buffered saline with protease
inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA). Following
centrifugal precipitation at 20 000 g for 20 min, the supernatant was removed and saved
(cytosolic fraction in immunoblots), and the membranal pellet was washed and precipitated
again by centrifugation. Final pellet was homogenized in 1.0 mL of 50 mM Tris pH 7.4.
Membranal protein fractions of 100 μg were used per assay, determined by BCA Protein Assay
Kit (Thermo Scientific, Waltham, MA, USA). Total ligand binding was determined following
incubation of membranal fractions with incrementing concentrations of radioligand for 2 h at
25°C. Non-specific ligand binding was determined using the same conditions with the addition
of non-radioactive ligands, 1 mM DA for D1DR and 1 μM sulpiride for D2DR. Bound
radioligand was separated using a Brandel harvester (Brandel, Gaithersburg, MD, USA).
Radioligand bound to the filter was measured by liquid scintillation counting. Specific ligand
binding values were calculated by subtracting non-specific ligand binding from total ligand
binding. The ligands used in the tests were: [3H]SCH23390 and [3H]raclopride as D1DR and
D2DR antagonists, respectively, and [3H]quinpirole as a D2DR agonist. The range for
radioactive materials used was between 0.03 nM and 4.0 nM (increments by serial dilution).
The effect of MsrA enzyme on quinpirole and raclopride binding was tested by using
recombinant yeast MsrA (10 μg) (Moskovitz et al. 1997) with 15 mM dithiothreitol (DTT; this
alone did not affect binding). D1DR binding to the agonist SKF82958 was determined using
the same conditions above, except for the addition of 2 nM [3H]SCH23390 to quantify the
competitive binding of non-radiolabeled SKF82958 ligand (performed because of limited
sources of commercially available radiolabeled D1DR agonists).
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GTPγS-induced inhibition of radiolabeled quinpirole binding to D2DR
The ability of agonists to stimulate the dissociation of GDP and association of GTP from G-
protein was assessed using GTPγS, a non-hydrolyzable analogue of GTP (Zhang et al. 2001).
When the agonist binds to the receptor, GDP is released from the G-protein and GTPγS binds
(Harrison and Traynor 2003). The G-protein uncoupling on [3H]quinpirole binding to the
D2DR was investigated by measuring the inhibition of [3H]quinpirole binding at incrementing
GTPγS concentrations. The membrane portion of homogenized striatal regions were isolated
and lysed in 5 mM Tris buffer by glass-Teflon homogenation. Membranal extracts (30 mg/
mL; 80 μg per assay) were incubated with [3H]quinpirole (1 nM) and GTPγS (0.1, 1, 10, 100,
and 1000 nM) in 50 mM Tris buffer for 2 h at 25°C in a total volume of 1 mL. To determine
non-specific binding, identical assays were performed in the presence of sulpiride (1 μM;
racemic mixture). Unbound ligand was removed by Brandel filtration and the remaining bound
ligand was quantified by liquid scintillation counting.
Stimulated release of DA in striatal brain sections in the presence of quinpirole and sulpiride
measured by fast scan cyclic voltammetry
Brain sections were prepared as previously described (Johnson et al. 2006). Mice were
anesthetized by isoflurane inhalation. The brain was immediately removed and placed in ice
cold artificial CSF. Artificial CSF consisted of 126 mM NaCl, 2.5 mM KCl, 1.2 mM
NaH2PO4, 2.4 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, 20 mM HEPES, and 11 mM D-
Glucose at pH 7.4 and was continuously saturated with 95% O2/5% CO2 throughout the
experiment. Coronal sections of 300 μm in thickness were made using a vibratome slicer (Leica
Microsystems, Bannockburn, IL, USA). A single section was placed in the superfusion
chamber with artificial CSF flowing at 34°C and a continuous rate of 2 mL/min. Each brain
section was equilibrated for 60 min prior to obtaining measurements. Quinpirole and sulpiride
in artificial CSF were maintained in a separate reservoir and introduced through a three-way
valve.
Carbon-fiber microelectrodes were fabricated as previously described (Kraft et al. 2009). A
single carbon-fiber with a 7 μm diameter (Goodfellow Cambridge Ltd., Oakdale, PA, USA)
was aspirated through a glass capillary tube (1.2 mm outer diameter, 0.68 mm inner diameter,
4 inches long, A-M Systems, Inc., Sequim, WA, USA) and pulled using a heated coil puller
(Narishige International USA, Inc., East Meadow, NY, USA). Electrodes were trimmed to 20
μm from the glass seal, further insulated with epoxy resin (EPON resin 815C, EPIKURE 3234
curing agent, Miller-Stephenson, Morton Grove, IL, USA), and then cured at 100°C for 1 h.
Prior to experimentation, electrodes were backfilled with 0.5 M potassium acetate.
A triangular waveform starting at −0.4 V, increasing to +1.0 V, and scanning back to −0.4 V
was applied at the carbon-fiber working electrode. A scan rate of 300 V/s was used with an
update rate of 10 Hz. A head-stage amplifier (UNC Chemistry Department Electronics Design)
was interfaced with a computer via breakout box and custom software provided by R.M.
Wightman and M.L.A.V. Heien. A choridated silver wire was used as an Ag/AgCl reference
electrode. The carbon fiber was inserted 100 μm into the dorsolateral caudate-putamen region
of the striatum. The fiber was between the prongs of a bipolar stimulation electrode (Plastics
One, Roanoke, VA, USA), which were separated by 200 μm. Current was measured at 0.6 V,
which is the oxidation potential for DA. DA release was measured in the presence of either 1
μM quinpirole or 5 μM sulpiride as previously described (Fawaz et al. 2009) using a 30-pulse
stimulus train at a stimulation frequency of 60 Hz. During stimulation and DA release,
stabilized scans of 15 s were collected every 2 min and averaged as 4-min time blocks.
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Locomotor activity measured by force-plate actometer
The force-plate actometer and methods of data analysis have been previously described (Fowler
et al. 2001). Briefly, the force-plate actometer consists of a low mass and highly stiff 5 mm
thick plate (28 cm × 28 cm). This plate is supported by four Sensotec Model 31 load cells (0–
250 g range). Each force plate is positioned below a Plexiglas cage that confines the mouse to
the force-sensing plate and is encased in sound-attenuating cubicle. Horizontal movements of
the mouse were recorded along the sensing surface with a spatial resolution of 1 mm and a
temporal resolution of 0.01 s.
The duration of recording sessions was based upon preliminary experiments and relevant
literature assessing spontaneous locomotor activity (Geter-Douglass et al. 1997; Usiello et
al. 2000; Wang et al. 2000). The effects of the drugs used on locomotor activity were apparent
within the initial period of 45 min following drug injection. Thus, 45-min periods were
determined to be sufficient to monitor the locomotor response to the performed treatments.
Total distance traveled per animal was measured and analyzed by 2-way ANOVA (two mouse
types) with repeated measures on the time block and session factors.
Administration of agonists of D1DR and D2DR for locomotor activity analyses
Prior to treating the mice with D1DR or D2DR agonists, the WT and MsrA−/− mice received
intraperitoneal injection with 0.9% saline as a vehicle control and spontaneous locomotor
activity was monitored for 45 min using force-plate actometers. After 4 days, the same mice
were injected with either quinpirole (D2DR agonist, 0.1 and 0.5 mg/kg) or SKF82958 (D1DR
agonist, 0.3 and 1.0 mg/kg) and locomotor activity was monitored for 45 min. A minimum of
4 days between trials was used to minimize potential carryover effects. Different sets of animals
were used for each drug to prevent cross-reactivity and carryover effects between drugs. The
drugs were administered at volume of 5 mL/kg.
MetO residues in recombinant long form of D2DR third intracellular loop
The long form of rat D2DR third intracellular loop (D2DRL-IC3) was expressed as a glutathione
S-transferase (GST) fusion protein in bacteria (gift from Dr. Kim Neve, Oregon Health &
Science University) and purified according to published procedures (Lan et al. 2009). The
protein was oxidized overnight with 200 mM H2O2 and excess oxidants were removed by
catalase. In parallel, oxidized protein was reduced with recombinant poly-His-tagged yeast
MsrA (10 μg) (Moskovitz et al. 1997) in the presence of 20 mM DTT for 1 h at 37°C (DTT
alone does not reduce MetO residues under these conditions). After reduction, all proteins (non-
treated, H2O2-treated, and MsrA-reduced) were subjected to gel-electrophoresis followed by
Commassie blue staining for the isolation of the corresponding GST-D2DRL-IC3. Bands
corresponding to the predicted weight of ~54 kDa were excised and protein was isolated. The
protein was subjected to tryptic digestion prior to analysis by a LCT Premier electrospray
ionization tandem mass spectrometer (Waters Corp., Milford, MA, USA). The mass
spectrometry analyses of the peptides and their MetO content were performed according to
previously published methods (Zhang et al. 2010).
Results
Expression levels and ligand binding capabilities of D2DR in MsrA−/− striatum
Postmortem brain sections from MsrA−/− and WT mice were immunostained with anti-D2DR
antibodies. The MsrA−/− striatal region exhibited higher reaction levels with the antibodies
compared with this region in WT mice (Fig. 1a). D2DR expression levels were quantified by
immunoblot analysis on brain extracts followed by densitometry analysis (Fig. 1b). Similar to
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the increase of DA in MsrA−/− brains (Oien et al. 2008), the up-regulation of the D2DR may
be part of compensatory response for the dysfunction of the DA system in the MsrA−/− brain.
The binding of the D2DR to appropriate ligands can reflect their expression levels and function
in signaling. Binding of the D2DR antagonists are independent of G-protein coupling and more
reflective of D2DR expression levels. Binding of the D2DR agonists are dependent on G-
protein coupling and more reflective of D2DR function in signaling. Accordingly, the
calculated Bmax value of D2DR antagonist [3H]raclopride was higher in MsrA−/− membranal
fractions (250 ± 20 fmole/mg protein) compared with the value of WT (140 ± 4 fmole/mg
protein) (Fig. 2a). In addition, the Kd value for [3H]raclopride in both mouse types was similar
(Kd of 0.70 ± 0.10 nM), suggesting no difference in the binding affinity of the bound antagonists
to D2DR (it is noteworthy that the Kd values in these mice are different than rats, see
‘Discussion’). The [3H]raclopride Bmax values also provide further supportive evidence to the
observed elevated levels of the D2DR in MsrA−/− brain (Fig. 1). The calculated Bmax value
of D2DR agonist [3H]quinpirole was lower in MsrA−/− membranal fractions (56 ± 7 fmole/
mg protein) when compared with the value of the WT (140 ± 10 fmole/mg protein), while the
Kd value for [3H]quinpirole binding was similar in both mouse types (0.40 ± 0.05 nM) (Fig.
2a). These observations suggest that the coupling ability of the MsrA−/− D2DR to the respective
G-proteins is compromised, in spite of the higher number of receptors in MsrA−/− mice (Fig.
1). In addition, adding recombinant MsrA to the binding reaction mixture caused significant
recovery of the MsrA−/− [3H]quinpirole Bmax value to the WT Bmax value (Fig. 2b). This latter
result strengthens the hypothesis that lack of MsrA enhances MetO formation in D2DR, which
affects D2DR function and expression. In contrast to relative D2DR agonist-to-antagonist
Bmax differences between the two mouse types (Fig. 2a and b), no significant differences were
found for D1DR ligand binding to the antagonist SCH23390 or agonist SKF82958 between
these mouse types (Fig. 2c and d). At relatively high concentrations, [3H]SCH23390 was bound
to MsrA−/− and WT striatal fractions to a similar extent (Fig. 2c). Similar results were found
when SKF82958 was used (Fig. 2d). The SKF82958 ligand was not radiolabeled, thus binding
efficiency was determined by its competitive binding in the presence of 2 nM [3H]SCH23390
as previously described (Nwaneshiudu and Unterwald 2009). The amounts of [3H]SCH23390
bound to the striatal fractions were significantly decreased (p < 0.05) by the presence of 16
nM of SKF82958. This supports the hypothesis that MsrA ablation primarily impacts the
D2DR.
G-protein coupling efficiency to D2DR in MsrA−/− striatum
The non-hydrolyzable GTPγS analog will reduce the binding of [3H]quinpirole to D2DR
(quinpirole binds with lower affinity to uncoupled D2DR compared with coupled receptors).
Consequently, competition curves were performed by inhibiting [3H]quinpirole binding with
increasing concentrations of GTPγS. Accordingly, the maximal inhibition from the
competition curve reflects the number of D2DR coupled to G-proteins, while the 50% binding
inhibition concentration (IC50) from the curve reflects the potency of GTPγS to dissociate the
D2DR and G-protein complex. The maximum binding of [3H]quinpirole to D2DR in MsrA−/
− was ~50% of the maximum binding of the agonist to the receptors in the WT brain (Fig. 3;
WT = 50 ± 6 and MsrA−/− = 26 ± 3 fmole/mg protein in the presence of 1 μM [3H]quinpirole).
The IC50 was found to be similar for both mouse types (10 ± 1 nM), which is in agreement
with current literature (Zhang et al. 2001). These data suggest reduced G-protein and D2DR
coupling in the MsrA−/− brain. Moreover, the similar IC50 in both mouse types suggests that
the dissociation rates of the receptors from the G-proteins are similar. The reduced interaction
of G-proteins with D2DR in MsrA−/− brains could be a consequence of either lower G-protein
expression or interference in the initial binding of G-proteins to the third intracellular loop of
D2DR. There was no significant difference in expression of Gαi/o proteins between the two
mouse types (Figure S1), suggesting that the observed limitation in MsrA−/− D2DR agonist
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binding is probably not because of reduced Gαi/o levels. Since the expression levels of these
G-proteins seem to be similar in the two mouse types (Figure S1), data in Fig. 3 are supportive
of compromised D2DR agonist binding in MsrA−/− brains (Fig. 2a) and also may reflect
interference in binding of MsrA−/− G-proteins to the third intracellular loop of D2DR.
Pre-synaptic stimulated dopamine release of MsrA−/− striatal tissue sections in response to
D2DR ligands
A shorter form of the D2DR, D2DRS, serves as an autoreceptor on the pre-synaptic membrane
of dopaminergic neurons. This receptor has a third intracellular loop that is truncated by 29
amino acids, but still retains four of the eight methionine residues. D2DRS has been previously
demonstrated to respond to the D2DR agonist quinpirole and D2DR antagonist sulpiride by
decreasing and increasing the pre-synaptic release of DA, respectively (Fawaz et al. 2009).
Using a similar experimental design as Fawaz et al., the pre-synaptic DA release in the striatal
area from MsrA−/− and WT coronal sections was measured in the presence of quinpirole (Fig.
4a and b) and sulpiride (Fig. 4c and d). Pre-synaptic DA release was detected by fast scan cyclic
voltammetry every 2 min, initially without any treatment and followed by treatment with a
saturating dose of quinpirole. In the presence of quinpirole, MsrA−/− sections were less
responsive than WT sections when both were compared to the respective initial stimulation
and detection without the presence of drug. The DA release of the MsrA−/− pre-synaptic
neurons was significantly higher than the decreased release of the WT pre-synaptic neurons
(p < 0.05; two-way repeated measures ANOVA). Moreover, the MsrA−/− pre-synaptic neurons
were also less responsive to sulpiride than WT. After sulpiride treatment, the changes in DA
concentration from the initial non-treated measurement of MsrA−/− slices were significantly
lower than the increased DA concentration changes of the WT (p < 0.05). These results suggest
that the D2DRS signaling is disrupted in MsrA−/− mice.
Locomotor activity of MsrA−/− mice after injections of dopamine receptor agonists
The in vitro and brain section findings suggest functional changes in the DA system that should
be expressed at the behavioral level. Consequently, we investigated the behavioral effects of
D1DR and D2DR selective agonists on locomotor activity in MsrA−/− and WT mice. A
significant difference in locomotor activity was observed between the mouse strains when
injected with quinpirole. At a dose of 0.5 mg/kg, the MsrA−/− exhibited ~40% more locomotor
activity than WT, and at a dose of 0.1 mg/kg the MsrA−/− exhibited ~35% more locomotor
activity than WT (Fig. 5a; repeated measures ANOVA for mouse type effect, p < 0.02). No
significant difference in locomotor activity was observed between the two mouse types when
injected with saline (Fig. 5), which is consistent with previous experiments (Oien et al.
2008). Given the higher expression level of the D2DR in MsrA−/− mice, these data suggest
that the compromised responsiveness of the MsrA−/− D2DRs to the inhibitory effect of
quinpirole may be because of irregularities in either DA binding or abnormal function of further
downstream signaling events. Moreover, the lack of a significant dose effect in the quinpirole
concentrations used is consistent with published data, illustrating by similar analyses that there
was no dose effect in mice even at broader and higher dose ranges (Wang et al. 2000).
In addition, MsrA−/− and WT mice were injected with two doses of the D1DR agonist
SKF82958, and ensuing locomotor activity behavioral effects were assessed in 45-min sessions
(Fig. 5b). The ANOVA applied to these distance traveled data indicated no effect of mouse
type, a significant effect of SKF82958 dose effect (repeated measures ANOVA; p < 0.01), and
no dose-by-type interaction. These data show that the D1DR agonist did not differentially affect
the two types of mice (no type effect, no interaction effect). As expected from the literature
for several types of inbred mice, SKF82958 substantially increased locomotor activity in the
dose range used here (Niimi et al. 2009). These data strengthen the idea that methionine
oxidation in the D2DR third cytoplasmic loop plays an important role in the MsrA−/−
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phenotype (the D2DR third intracellular loop contains eight methionines, and the D1DR C-
terminus cytoplasmic region contains only one methionine; both of these regions are directly
involved in signal transduction).
MetO residues in recombinant long form D2DR third intracellular loop
Oxidation vulnerability was examined with recombinant GST-D2DRL-IC3 and peroxide
exposure. Non-H2O2 oxidized GST-D2DRL-IC3 protein, H2O2 oxidized GST-D2DRL-IC3
protein, and H2O2 oxidized GST-D2DRL-IC3 proteins treated with MsrA were all subjected
to mass spectrometry analysis following gel-electrophoresis separation and tryptic digestion.
The procedure used to detect peptides by this mass spectrometry analysis (Zhang et al. 2010)
normally causes some methionine oxidation. To compensate for this, averaged MetO levels
detected in the non-H2O2 oxidized GST-D2DRL-IC3 peptides were subtracted from the
H2O2 oxidized forms of the protein (+/− MsrA and DTT). A 17-amino-acid peptide produced
by collision-induced dissociation was found to contain the highest quantity of oxidized
methionine (276-AQELEMEMLSSTSPPER-292; Fig. 6). Furthermore, the Met283 residue
(present in daughter ion Y10) of the peptide was found to be relatively more oxidized in
comparison with the Met281 residue (present in daughter ion Y12; data not shown). The net
oxidation level of Met283 treated with H2O2 in vitro was on average 2% (Fig. 6). This oxidation
level resembles the basal physiological level of MetO in unpublished observations and in yeast
cells without H2O2 in the growth media (Moskovitz et al. 1997). Accordingly, the current in
vitro condition of oxidation may resemble physiological methionine oxidation. The addition
of MsrA and DTT to oxidized GST-D2DRL-IC3 protein was able to reduce the sulfoxide of
Met283 by 60% (Fig. 6). The MsrA enzyme can reduce only the S-form of MetO. Empirically,
the distribution ratio of S to R forms of MetO is 1 : 1 (Oien and Moskovitz 2008). Typically,
we observed that in vitro oxidation of methionine by H2O2 results in 60% S-MetO and 40%
R-MetO (determined by amino acid analysis separation; unpublished results). Thus, the ability
of the MsrA to reduce 60% of the total oxidized Met283 reflects the expected maximum
reduction capability of the enzyme in an expected MetO racemic mixture of R and S forms
following methionine oxidation by H2O2. In addition, the preferred oxidation of Met283
suggests this residue is more vulnerable to oxidation and also readily accessible to the reducing
function of MsrA.
Discussion
This study describes for the first time the possible effects of methionine oxidation on DA
receptor function in vivo by using MsrA−/− mice. Previously, we observed an inverse
relationship between abnormally high levels of DA accompanied by lowered locomotor
activity in MsrA−/− mice (Oien et al. 2008). This is paradoxical because chronically low levels
of brain DA are associated with Parkinson’s disease-like motor effects including low levels of
locomotor activity. These unexpected results led us to investigate that the alteration of DA
receptor function and expression may be involved.
Both the D1DR and the D2DR modulate striatal information processing that is integral to the
translation of cortical plans into actions by providing for the expression of selected motor
responses with concurrent suppression of unwanted responses (‘responses’ may be cognitive
or motor). The D2DR are of particular clinical interest because of their role in neuropsychiatric
disorders, such as schizophrenia, where D2DR antagonists are therapeutic (Lieberman et al.
2008), or their role in the movement disorder, Parkinson’s disease, where D2DR agonists are
known to benefit patients (Pahwa et al. 2004). Thus, we predicted a reduced expression of
striatal D2DR in MsrA−/− mice to explain the relative lower locomotor activity (Oien et al.
2008). Surprisingly, there was an increase of D2DR expression in MsrA−/− mice (Fig. 1).
Higher levels of [3H]raclopride binding to D2DR confirmed this increase (Fig. 2). The higher
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protein levels of the D2DR in MsrA−/− may be part of a compensatory mechanism for the
accumulation of oxidized D2DR. In spite of the higher D2DR levels observed, the binding of
[3H]quinpirole suggests a compromised agonist binding of the D2DR in MsrA−/− brain (Fig.
2a). Supportive in vivo data to this phenomenon are demonstrated by the lesser D2DR agonist
inhibitory effect on locomotor function in MsrA−/− mice (Fig. 5a). Agonist occupation of G-
protein coupled receptors leads to a cellular response that wanes, or desensitizes, with
prolonged agonist exposure. MetO in the intracellular loops of the D2DR may cause a
conformational change that may result in uncoupling of the receptor to G-protein subunits. The
relative compromised binding of the D2DR to [3H]quinpirole suggests lower efficiency in
D2DR-G-protein coupling. Indeed, our data show that although the levels of Gαi/o are similar
in both mouse types (Figure S1), the coupling of D2DR to G-proteins is reduced by ~50% in
MsrA−/− relative to WT brain (Fig. 3). This suggests that the total Gαi/o coupling capacity is
reduced in MsrA−/− brain rather than their coupling affinity to D2DR.
The ability of MsrA to restore D2DR agonist binding in MsrA−/− striatal extracts (Fig. 2b)
supports the theory that methionine oxidation of D2DR occurs in the MsrA−/− brain.
Accordingly, it may be beneficial to cause striatal over-expression of Msr to prevent MetO
related abnormalities manifested by oxidized D2DR. Furthermore, the selectivity of the effect
of methionine oxidation on D2DR (by MsrA ablation) was demonstrated by the similar binding
of D1DR to striatal extracts in both mouse types (Fig. 2c and d). Data presented in Fig. 4 suggest
the autoreceptor function of D2DR in MsrA−/− striatum is compromised in its functional
response to quinpirole and sulpiride compared to WT D2DRS. The in vivo observation that
MsrA−/− mice are less responsive to the inhibitory effect of quinpirole on locomotor activity
(Fig. 5a) supports the conclusion that there is a general malfunction of MsrA−/− D2DR.
Furthermore, the in vivo specificity of the MsrA ablation effect to D2DR is strengthened by
the similar response of both mouse types to D1DR agonist (Fig. 5b). According to the literature,
the use of the administrated doses of 0.1 and 0.5 mg/kg quinpirole are within the common range
used in mice. In mice, there is no increased locomotor response as the dose is increased; instead,
a suppression of locomotor activity is observed (Geter-Douglass et al. 1997;Usiello et al.
2000;Wang et al. 2000). Mice are different from rats in their response to quinpirole. In rats
there is an increase of locomotor response with a higher quinpirole dose (Eilam et al.
1991;Koeltzow et al. 2003). This observation maybe is linked to observed difference in the
ligand Kd values in rats (Levant et al. 1992) vs. mice (current study).
Taken together, it is suggested that lack of MsrA leads to methionine oxidation in both long
and short forms of D2DR and diminishes their overall function efficacy. The general lowered
MsrA−/− response to quinpirole, both in vitro and in vivo (Figs 2 and 5) implies that conserved
regions of both D2DR subtypes are primarily affected in the MsrA−/− mouse (this does not
exclude involvement of the 29 amino acid sequence that is not present in the D2DRS). The
compromised G-protein coupling in MsrA−/− may be a result of oxidative modification of
specific methionine residues, especially in the cytoplasmic loops of the D2DR that are
important for G-proteins coupling (i.e. D2DRL-IC3) (Montmayeur et al. 1993;Ilani et al.
2002). To assess the possibility of methionine oxidation in D2DRL-IC3 and reversal by MsrA
in vitro, a recombinant GST-D2DRL-IC3 protein was oxidized and treated with recombinant
MsrA. An oxidation of a specific methionine (Met283) in recombinant GST-D2DRL-IC3
protein occurred and was reduced to methionine by 60% with MsrA (Fig. 6). Met283 is present
in both subtypes of D2DR and may be an important target for oxidation that affects the general
function of this receptor. Future experiments are underway to monitor in vivo MetO levels and
location in the D2DR of MsrA−/− mice. Overall, the collective evidence indicates that primarily
D2DR related signaling is affected in MsrA−/− mice. However, the contributions of other
signaling events to the observed abnormalities will still need further investigations.
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Mechanistically, we suggest that oxidation of specific methionine residues may also affect
phosphorylation of adjacent amino acids in D2DRL-IC3, thereby altering DA signal
transduction pathways. For example, a regulatory role of MetO in protein phosphorylation was
recently reported (Emes 2009; Hardin et al. 2009; Oien et al. 2009). Accordingly, it is possible
that specific MetO residues in D2DRL-IC3 inhibit phosphorylation events that are important
for proper coupling of the receptor to G-proteins as well (Namkung et al. 2009).
Our data can be interpreted to suggest that lack of MsrA in mouse brain causes D2DR
malfunction via G-protein uncoupling leading to the production of higher DA levels (as a
potential compensatory mechanism), reduced locomotor activity, and diminished behavioral
responsiveness to D2DR agonists (Oien et al. 2008). Understanding the role of MsrA and MetO
in DA physiology may result in identifying other proteins and neurotransmitter receptors that
are altered by oxidative modification of methionine.
Recently, it was reported that mutations in the upstream region of MsrA may be potential
markers for schizophrenia. If this proves true, research clearly supports the relevance of the
MsrA−/− DA system to the occurrence of DA-related abnormal behavior (Walss-Bass et al.
2009).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Immunohistochemistry and immunoblot analyses of D2DR in MsrA−/− and WT striatum. (a)
Immunohistochemistry of coronal brain sections using primary antibodies against D2DR.
Slides were visualized using light microscope with a 100× objective lens. Brownish structures
correspond to the presence of D2DR. Scale bars represent 10 μm. (b) Immunoblot analysis
using primary antibodies against D2DR. Representative bands are shown in the small window
followed by densitometry analysis for the corresponding D2DR band in each extract (relative
density in WT represents 100%; p < 0.01, t-test). The densities of D2DR were corrected for
the relative densities of β-actin.
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Binding efficiency of ligands to D2DR and D1DR in MsrA−/− and WT membranes. Specific
ligand binding was calculated from subtracting non-specific ligand binding from total ligand
binding as described in ‘Materials and Methods’. (a) Representative [3H]raclopride and [3H]
quinpirole specific ligand binding curves of D2DR. (b) Bmax of [3H]quinpirole binding
presented as percent of WT Bmax value (represents 100% binding) in the absence (Control)
and presence of recombinant yeast MsrA (rMsrA Added). (c) Binding of [3H]SCH23390 at a
saturating concentration (Bmax value WT, under these conditions, represents 100% binding).
(d) Relative binding of [3H]SCH23390 at a concentration of 2 nM (as in panel c) in the presence
of 2 nM and 16 nM SKF82958 concentrations. For all graphs, n = 3. Significance is denoted
by * or † indicating p < 0.05 using t-test for difference by mouse type or by condition,
respectively.
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Inhibition of D2DR agonist binding in striatal membrane extracts of MsrA−/− and WT mice
in the presence of GTPγS. The Y axis values of the graph represent the specific binding
percentage of [3H]quinpirole at GTPγS concentrations of 0.1, 1, 10, 100, and 1000 nM. The
value at 100% specific binding represents maximum binding of WT D2DR to [3H]quinpirole
at 0.1 nM GTPγS. The maximum binding values were not significantly different from values
obtained in the absence of GTPγS; data not shown, n = 3.
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DA release in striatal sections from MsrA−/− and WT mice treated with D2DR agonist and
antagonist. Coronal sections were stimulated using a 30 pulse-stimulus train and DA scans
were collected by fast scan cyclic voltammetry. (a) A representative stimulated DA release
plot generated from measurements in the presence and absence of quinpirole. WT, open
squares; MsrA−/−, filled diamonds. (b) The DA release measured in 4-min time blocks of WT
and MsrA−/− sections in the presence of quinpirole. The basal initial measurements without
drug treatment (time block 0) were set to 100%. All subsequent measurements with quinpirole
are represented as a percentage of this value. (c) A representative stimulated DA release plot
generated from measurements obtained in the presence and absence of sulpiride. WT, open
squares; MsrA−/−, filled diamonds. (d) The DA release measured in 4-min time blocks of WT
and MsrA−/− sections in the presence of sulpiride. The initial basal measurements without
treatment (time block 0) were set to 100%. All subsequent measurements with sulpiride are
represented as a percentage of the initial 100% values. For both experiments, n = 3 and p <
0.05 for genotype determined by two-way repeated measures ANOVA. The basal DA
concentrations in the absence of drug were WT = 1.63 ± 0.44 μM and MsrA−/− = 5.47 ± 0.36
μM.
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Locomotor activity after D2DR and D1DR agonist administration in MsrA−/− and WT mice.
Total distance traveled was measured for 45 min after intraperitoneal injections of saline
(vehicle) or indicated drug. (a) Quinpirole injection at doses of 0.5 mg/kg and 0.1 mg/kg. WT,
n = 7; MsrA−/−, n = 10. †p < 0.01 for quinpirole effect and *p < 0.02 for the genotype effect,
determined by ANOVA. (b) SKF82958 injection at doses of 0.3 mg/kg and 1.0 mg/kg. WT,
n = 7; MsrA−/−, n = 10. There was no significant effect of mouse type on SKF82958 effect,
SKF82958 increased locomotor activity in the dose range used (†p < 0.01) and no dose-by-
type interaction was detected; determined by ANOVA.
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Oxidized methionine residues in D2DRL-IC3 recombinant protein. The short and long form
D2DR differ by a 29-amino-acid region in the third cytoplasmic loop, which begins after amino
acid 241 in the rat sequence (underlined). The methionines (m) are in bold. The corresponding
recombinant fusion protein GST-D2DRL-IC3 was isolated and resulting peptides were
subjected to tandem mass spectrometry after trypsin digestion. The sequence of the major
oxidized peptide identified is shown and also indicated in the sequence by parenthesis.
Representative relative signal levels for the daughter ions of the major peptide detected after
collision-induced fragmentation are presented as relative intensity of each ion. The difference
in percent methionine (Y10) oxidation between the presence and absence of rMsrA was found
to be significant (three experiments, p < 0.05 by t-test).
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